---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-093832"
form_type: "8-K"
ticker: "FBLG"
cik: "0001958777"
company_name: "FibroBiologics, Inc."
filed_at: "2025-07-03T23:59:59+00:00"
generated_at: "2026-05-18T09:31:25.095954+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# FibroBiologics receives Nasdaq bid price deficiency notice; 180 days to cure

## Summary
- Nasdaq notified FibroBiologics on July 1, 2025 that common stock closing bid price was below $1.00 for 30 consecutive trading days.
- Company has until December 29, 2025 to regain compliance by maintaining $1.00+ closing bid for 10 consecutive business days.
- If not cured by deadline, FibroBiologics may qualify for a second 180-day period subject to meeting other listing standards.
- Failure to cure could lead to delisting; Company may consider options to regain compliance, no guarantee of success.

## SEC filing metadata
- accession: 0000950170-25-093832
- form_type: 8-K
- ticker: FBLG
- cik: 0001958777
- company_name: FibroBiologics, Inc.
- filed_at: 2025-07-03T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1958777/000095017025093832/0000950170-25-093832-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1958777/000095017025093832/fblg-20250701.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-093832
- JSON: https://secwatch.observer/filing/0000950170-25-093832.json
- Plain text: https://secwatch.observer/filing/0000950170-25-093832.txt

## Key facts
- Listing & Compliance Notices
  FibroBiologics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: July 1, 2025, FibroBiologics, Inc. (the “Company”) received a notification letter from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the closing bid price of the Company’s shares of common stock was below the minimum closing bid price of $1.00 per share during the last 30 consecutive trading days (the “Notice”), as required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The Notice has no immediate impact on the listing of the Company’s common stock, which will continue to be listed a
  evidence_url: https://www.sec.gov/Archives/edgar/data/1958777/000095017025093832/0000950170-25-093832-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.